Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies, Cancer Centers to Study Breast Cancer Polygenic Risk Score Impact

NEW YORK (GenomeWeb) – Genetic Technologies said today that its CLIA lab subsidiary Phenogen will be working with two cancer centers — Memorial Sloan Kettering in New York and the University of Cambridge in the UK — to study how polygenic risk scores impact the therapy decisions made by women who are BRCA mutation carriers.

In the study, led by MSKCC chief of breast medicine Mark Robson, Genetic Technologies will provide SNP genotyping through the Phenogen lab on a "fee for service basis," while investigators from the two collaborating institutions track whether the test results impact women's "decisional conflict" regarding preventive breast-removal surgery.

The company will design a new assay for the study, but the fundamental technology employed will be similar to the firm's existing BrevaGenplus breast cancer test.

According to Genetic Technologies, the resulting data could inform the design of future pipeline products. If the first phase of the study is successful, other US institutions have also expressed an interest in participating.

Last year, the company described a similar project with the University of Melbourne aimed at exploring an extended use of the Brevagen test in women with family history of breast cancer.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.